Who owns MoonLake Immunotherapeutics (MLTX)? Elite investor 13F holders
2 tracked elite investors reported holding MoonLake Immunotherapeutics as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis,…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | Moonlake Immunotherapeutics | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 65526421.00 USD | 3365507.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | Moonlake Immunotherapeutics | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 12524428.00 USD | 643268.000000 | Shares | add | Original filing |
| Tudor Investment | Moonlake Immunotherapeutics | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.